Emerging roles of vasoactive intestinal peptide: A new approach for autoimmune therapy

Annals of the Rheumatic Diseases

Volumn 66, Issue SUPPL. 3, 2007, Pages

  Gonzalez Rey, Elena ^b   Anderson, Per ^c   Delgado, Mario ^a,c  

^a CSIC   (Spain)

^b UNIVERSITY OF SEVILLE   (Spain)

^c INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CORTISONE; INSULIN; VASOACTIVE INTESTINAL POLYPEPTIDE;

ADAPTIVE IMMUNITY; ANTIINFLAMMATORY ACTIVITY; AUTOIMMUNE DISEASE; CELL ACTIVITY; CLINICAL RESEARCH; CLINICAL TRIAL; CONFERENCE PAPER; DRUG EFFECT; DRUG MECHANISM; EFFECTOR CELL; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOTHERAPY; INNATE IMMUNITY; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REGULATORY T LYMPHOCYTE; TH1 CELL;

ANTI-INFLAMMATORY AGENTS; AUTOIMMUNE DISEASES; AUTOIMMUNITY; HUMANS; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; IMMUNITY, NATURAL; IMMUNOSUPPRESSIVE AGENTS; MODELS, IMMUNOLOGICAL; T-LYMPHOCYTES, REGULATORY; TH1 CELLS; VASOACTIVE INTESTINAL PEPTIDE;

EID: 35648966136     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2007.078519     Document Type: Conference Paper

References (68)

1. Firestein GS. Evolving concepts of rheumatoid arthritis. Nature 2003;423:356-61.
2. Mills KHG. Regulatory T cells: friend or foe in immunity to infection? Nat Rev Immunol 2004;4:841-55.
3. Bluestone JA. Regulatory T-cell therapy: is it ready for the clinic? Nat Rev Immunol 2005;5:343-9.
4. Shevach EM. From vanilla to 28 flavors: multiple varieties of T regulatory cells. Immunity 2006;25:195-201.
5. Ehrenstein MR, Evans JG, Singh A, Moore S, Warnes G, lsenberg DA, et al. Compromised function of regulatory T cells in rheumatoid arthritis and reversal by anti-TNFα therapy. J Exp Med 2004;200:277- 85.
6. + T-cells from patients with type 1 diabetes. Diabetes 2005;54:92-9.
7. + regulatory T cells in patients with multiple sclerosis. J Exp Med 2004;199:971-9.
8. Wan YY, Favell RA. The roles for cytokines in the generation and maintenance of regulatory T cells. Immunol Rev 2006;212:114-30.
9. Gonzalez-Rey Ë, Chorny A, Delgado M. Regulation of immune tolerance by antiinflammatory neuropeptides. Nat Rev Immunol 2007;7:52-63.
10. Gonzalez-Rey E, Delgado M. Anti-inflammatory neuropeptide receptors: new therapeutic targets for immune disorders? Trends Pharmacol Sci. 2007. doi: 10.1016/j.tips.2007.07.001/.
11. Delgado M, Pozo D, Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol Rev 2004;56:249-90.
12. Said SI, Mutt V. Polypeptide with broad biological activity: isolation from small intestine. Science 1970;169:1217-8.
13. Delgado M, Ganea D. Cutting edge: is vasoactive intestinal peptide a type 2 cytokine? J Immunol 2001;166:2907-12.
14. Banner KH, Trevethick MA. PDE4 inhibition: a novel approach for the treatment of inflammatory bowel disease. Trends Pharmacol Sci 2004;25:430-6.
15. De la Fuente M, Delgado M, Gomariz RP. VIP modulation of immune cell functions. Adv Neuroimmunol 1996;6:75-91.
16. Delgado M, Muñoz-Elías EJ, Gomariz RP, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide enhance IL-10 production by murine macrophages: in vitro and in vivo studies. J Immunol 1999;162:1707-16.
17. + T cells. J Leukoc Biol 2004;75:1122-30.
18. Tuncel N, Tore F, Sahinturk V, Ak D, Tuncel M. Vasoactive intestinal peptide inhibits degranulation and changes granular content of mast cells: a potential therapeutic strategy in controlling septic shock. Peptides 2000;21:81-9.
19. Delgado M, Leceta J, Abad C, Martinez C, Ganea D, Gomariz RP. Shedding of membrane-bound CD14 from lipopolysaccharide-stimulated macrophages by vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide. J Neuroimmunol 1999;99:61-71.
20. Gomariz RP, Arranz A, Abad C, Torroba M, Martinez C, Rosignoli F, et al. Time-course expression of Toll-like receptors 2 and 4 in inflammatory bowel disease and homeostatic effect of VIP. J Leukoc Biol 2005;78:491-502.
21. Martinez C, Abad C, Delgado M, Arranz A, Juarranz MG, Rodrigurez-Henche N, et al. Anti-inflammatory role in septic shock of pituitary adenylate cyclase-activating polypeptide receptor. Proc Natl Acad Sci USA 2002;99:1053-8.
22. Szema AM, Hamidi SA, Lyubsky S, Dickman KG, Mathew S, Abdel-Razek T, et al. Mice lacking the VIP gene show airway hyperresponsiveness and airway inflammation, partially reversible by VIP. Am J Physiol Lung Cell Mol Physiol 2006;291:880-6.
23. Delgado M, Leceta J, Gomariz RP, Ganea D. VIP and PACAP stimulate the induction of Th2 responses by upregulating B7.2 expression. J Immunol 1999;163:3629-35.
24. Voice JK, Dorsam G, Lee H, Kong Y, Goetzl EJ. Allergic diathesis in transgenic mice with constitutive T cell expression of inducible VIP receptor. FASEB J 2001;15:2489-96.
25. Goetzl EJ, Voice JK, Shen S, Dorsam G, Kong Y, West KM, et al. Enhanced delayed-type hypersensitivity and diminished immediate type hypersensitivity in mice lacking the inducible VPAC(2) receptor for VIP. Proc Natl Acad Sci USA 2001;98:13854-9.
26. Voice J, Grinninger C, Kong Y, Bangale Y, Paul S, Goetzl EJ. Roles of vasoactive intestinal peptide (VIP) in the expression of different immune phenotypes by wildtype mice and T cell-targeted type II VIP receptor transgenic mice. J Immunol 2003;170:308-14.
27. Delgado M, Munoz-Elias EJ, Gomariz RP, Ganea D. VIP and PACAP inhibit IL-12 production in LPS-stimulated macrophages. Subsequent effect on IFNγ synthesis by T cells. J Neuroimmunol 1999;96:167-81.
28. Jiang X, Jing H, Ganea D. VIP and PACAP down-regulate CXCL10 (IP-10) and up-regulate CCL22 (MDC) in spleen cells. J Neuroimmunol 2002;133:81-94.
29. Delgado M, Gonzalez-Rey E, Ganea D. VIP/PACAP preferentially attract Th2 versus Th1 cells by differentially regulating the production of chemokines by dendritic cells. FASEB J 2004;18:1453-5.
30. Sharma V, Delgado M, Ganea D. Granzyme B, a new player in activation-induced cell death, is down-regulated by vasoactive intestinal peptide in Th2 but not Th1 effectors. J Immunol 2006;176:97-110.
31. Delgado M, Leceta J, Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide promote in vivo generation of memory Th2 cells. FASEB J 2002;16:1844-6.
32. Rosignoli F, Torroba M, Juarranz Y, Garcia-Gomez M, Martinez C, Gomariz RP, et al. VIP and tolerance induction in autoimmunity. Ann NY Acad Sci 2006;1070:525-30.
33. Voice J, Donnelly S, Dorsam G, Dolganov G, Paul S, Goetzl EJ. c-Maf and JunB mediation of Th2 differentiation induced by the type 2 G protein-coupled receptor (VPAC2) for vasoactive intestinal peptide. J Immunol 2004;172:7289-96.
34. + regulatory T cells in vivo. J Leukoc Biol 2005;78:1327-38.
35. + regulatory T cells with therapeutic effect on collagen-induced arthritis. Arthritis Rheum 2006;54:864-76.
36. Fernandez-Martin A, Gonzalez-Rey E, Chorny A, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory T cells during experimental autoimmune encephalomyelitis. Eur J Immunol 2006;36:318-26.
37. - cells to develop suppressive activity: the role of IL-2, TGF-β, and IL-10. J Immunol 2004;172:5213-21.
38. Hackstein H, Thomson AW. Dendritic cells: emerging pharmacological targets of immunosuppressive drugs. Nat Rev Immunol 2004;4:24-34.
39. Rutella S, Danese S, Leone G. Tolerogenic dendritic cells: cytokine modulation comes of age. Blood 2006;108:1435-40.
40. Chorny A, Gonzalez-Rey E, Fernandez-Martin A, Pozo D, Ganea D, Delgado M. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders. Proc Natl Acad Sci USA 2005;102:13562-7.
41. Gonzalez-Rey E, Delgado M. Therapeutic treatment of experimental colitis with regulatory dendritic cells generated with vasoactive intestinal peptide. Gastroenterology 2006;131:1799-811.
42. Delgado M, Gonzalez-Rey E, Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J Immunol 2005;175:7311-24.
43. Gonzalez-Rey E, Chorny A, Fernandez-Martin A, Ganea D, Delgado M. Vasoactive intestinal peptide generates human tolerogenic dendritic cells that induce CD4 and CD8 regulatory T cells. Blood 2006;107:3632-8.
44. Gilliet M, Liu YJ. Generation of CD8 T regulatory cells by CD40 ligand activated plasmacytoid dendritic cells. J Exp Med 2002;195:695-704.
45. Delgado M, Martinez C, Pozo D, Calvo JR, Leceta J, Ganea D, et al. Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase-activating polypeptide (PACAP) protect mice from lethal endotoxemia through the inhibition of TNF-α and IL-6. J Immunol 1999;162:1200-5.
46. Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat Med 2001;7:563-8.
47. Yin H, Cheng H, Yu M, Zhang F, Gao Y, Lin J, et al. Vasoactive intestinal peptide ameliorates synovial cell functions of collagen-induced arthritis rats by down-regulating NF-kappaB activity. Immunol Invest 2005;34:153-69.
48. Zafirova Y, Yordanov M, Kalfin R. Antiarthritic effect of VIP in relation to the host resistance against Candida albicans infection. Int Immunol 2004;16:1125-31.
49. Williams RO. Therapeutic effect of vasoactive intestinal peptide in collagen-induced arthritis. Arthritis Rheum 2002;46:271-3.
50. Abad C, Martinez C, Juarranz MG, Arranz A, Leceta J, Delgado M, et al. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 2003;124:961-71.
51. Herrera JL, Fernandez-Montesinos R, Gonzalez-Rey E, Delgado M, Pozo D. Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice. Ann NY Acad Sci 2006;1070:337-41.
52. Gonzalez-Rey E, Fernandez-Martin A, Chorny A, Martin J, Pozo D, Ganea D, et al. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: downregulation of inflammatory and autoimmune responses. Am J Pathol 2006;168:1179-88.
53. Li H, Mei Y, Wang Y, Xu L. Vasoactive intestinal polypeptide suppressed experimental autoimmune encephalomyelitis by inhibiting T helper 1 responses. J Clin Immunol 2006;26:430-7.
54. Lodde BM, Baum BJ, Tak PP, Illei G. Effect of human vasoactive intestinal peptide gene transfer in a murine model of Sjorgre's disease. Ann Rheum Dis 2006;65:195-200.
55. Kojima M, Ito T, Oono T, Hisano T, lgarashi H, Arita Y, et al. VIP attenuation of the severity of experimental pancreatitis is due to VPAC1 receptor-mediated inhibition of cytokine production. Pancreas 2005;30:62-70.
56. Szliter EA, Lighvani S, Barret RP, Hazlett LD. Vasoactive intestinal peptide balances pro- and anti-inflammatory cytokines in the Pseudomonas aeruginosa-infected cornea and protects against corneal protection. J Immunol 2007;178:1105-14.
57. Keino H, Kezuka T, Takeuchi M, Yamakawa N, Hattori T, Isui M. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch Ophthalmol 2004;122:1179-84.
58. Bangale Y, Karle S, Planque S, Zhou YX, Taguchi H, Nishiyama Y, et al. VIPase autoantibodies in Fas-defective mice and patients with autoimmune disease. FASEB J 2003;17:628-35.
59. + regulatory T cells in vivo. J Exp Med 2003;198:249-58.
60. + regulatory T cells in the steady state. J Exp Med 2003;198:737-46.
61. Gonzalez-Rey E, Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol Med 2007;13:241-51.
62. Petkov V, Mosgoeller W, Ziesche R, Raderer M, Stiebellehner L, Vonbank K, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111:1339-46.
63. Gotthardt M, Boermann OC, Behr TM, Behe MP, Oyen WJ. Development and clinical application of peptide-based radiopharmaceuticals. Curr Pharm Des 2004;10:2951-63.
64. Bolin DR, Michalewsky J, Wasserman MA, O'Donnell M. Design and development of a vasoactive intestinal peptide analog as a novel therapeutic for bronchial asthma. Biopolymers 1995;37:57-66.
65. Onyuksel H, Ikezaki H, Patel M, Gao XP, Rubinstein I. A novel formulation of VIP in sterically stabilized micelles amplifies vasodilation in vivo. Pharm Res 1999;16:155-60.
66. Sethi V, Onyuksel H, Rubinstein I. Liposomal vasoactive intestinal peptide. Methods Enzymol 2005;391:377-95.
67. Sedo A, Duke-Cohan JS, Balaziova E, Sedova LR. Dipeptidyl peptidase IV activity and/or structure homologs: contributing factors in the pathogenesis of rheumatoid arthritis? Arthritis Res Ther 2005;7:253-69.
68. Foey AD, Field S, Ahmed S, Jain A, Feldmann M, Brennan FM, et al. Impact of VIP and cAMP on the regulation of TNF-alpha and IL-10 production: implications for rheumatoid arthritis. Arthritis Res Ther 2003;5:317-28.